Is BLTE or BOLT more undervalued in 2026?

CirclFi compares Belite Bio, Inc (BLTE) and Bolt Biotherapeutics, Inc. (BOLT) using 13 institutional-grade valuation models. BLTE has a Quality of Company score of 4.7/10 while BOLT scores 5.9/10.

Which is a better buy — BLTE or BOLT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BLTE and BOLT valuations compare?

BLTE at $148.00 and BOLT at $5.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BLTE vs BOLT Valuation Comparison 2026 — Intrinsic Value Analysis

BLTE

Biotechnology

Belite Bio, Inc

Quality

4.7

out of 10

Value Trap

SAFE

Price

$148.00

Last close

Models

10/13

Active

BOLT

Biotechnology

Bolt Biotherapeutics, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$5.30

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BLTE Fair Value	BLTE Upside	BOLT Fair Value	BOLT Upside
Bayesian DCF	Intrinsic	$49.41	-66.6%	$0.54	-88.5%
Earnings Power Value	Intrinsic	$77.24	-52.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$7.86	-94.7%	$17.21	+224.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BLTE vs BOLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BLTE vs BOLT — Which Stock Is More Undervalued?

BOLT scores higher with a 5.9/10 quality rating vs BLTE's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Belite Bio, Inc (BLTE) and Bolt Biotherapeutics, Inc. (BOLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BLTE currently trades at $148.00 with a QOC of 4.7/10, while BOLT trades at $5.30 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).